Competing interests
MR, Dysautonomia
HEART, LUNG, DYSAUTONOMIA
AK and PL disclose funding from Swedish Heart–Lung foundation, Stockholm Council and Oura Health Oy for the current trial. MS discloses funding from Swedish Research Council and Dysautonomia International during the trial and previously from HLF. MS also disclose consulting fee from Swedish agency for health technology assessment of social services, speaker honoraria from Orion Pharma, Werfen and has filed a patent for pharmacological treatment in post-COVID POTS. JK disclose consulting fee for statistical work in this trial. AH, EB, SEG, SAE, JK, JB, MNB, MR declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.